Third Rock Ventures — Activity | F4

Team Portfolio Raise Read Contact

F4/Third Rock Ventures/Activity

Third Rock Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Led Terremoto Biosciences' $108M Series C to advance selective AKT1-inhibitors in oncology and hereditary hemorrhagic telangiectasia.

Terremoto Biosciences

Terremoto Biosciences Third Rock Ventures

thirdrockventures.comAPR 15, 2026

APR 15, 2026

Milestone

Portfolio company Seaport Therapeutics filed to go public in April 2026.

Seaport Therapeutics

Seaport Therapeutics Third Rock Ventures

bizjournals.comAPR 2026

APR 2026

Exit

Candid Therapeutics merged with Rallybio Corporation in March 2026.

Candid Therapeutics

Candid Therapeutics Third Rock Ventures

thirdrockventures.comMAR 2026

MAR 2026

Exit

Portfolio company Synnovation Therapeutics acquired by Novartis for its pan-mutant selective PI3Kα inhibitor program.

Synnovation Therapeutics

Synnovation TherapeuticsThird Rock Ventures

thirdrockventures.comMAR 2026

MAR 2026

3 investments· APR 2025 – JUL 2025Show all

Investment

Led ARTBIO's $132M Series B for alpha radioligand therapies in radiopharmaceuticals.

ARTBIO

ARTBIO Third Rock Ventures

dealroom.coJUL 2025

JUL 2025

Investment

Invested in Corvia Medical's $55M Late VC round for transcatheter structural heart device innovations.

Corvia Medical

Corvia Medical Third Rock Ventures

dealroom.coJUN 2025

JUN 2025

Investment

Led Merida Biosciences' $121M Series A for precision immunology targeting autoimmune and allergic disorders.

Merida Biosciences

Merida Biosciences Third Rock Ventures

dealroom.coAPR 2025

APR 2025